• TDK establishes Asia-Pacific Regional Headquarters (APAC RHQ) in India, effective 1 April 2026
• APAC RHQ will be operated by TDK Asia-Pacific Pvt. Ltd., a new legal entity to be established in India, and TDK Singapore Pte. Ltd., forming a dual-city administrative structure
• The RHQ is part of ‘TDK Transformation’, the company’s Long-term Vision

SAN JOSE, Calif., March 2, 2026 /PRNewswire/ — TDK Corporation (TSE: 6762) announces the establishment of its Asia-Pacific Regional Headquarters (APAC RHQ) in Bengaluru, India—the company’s fifth regional headquarters alongside Japan, Europe, the Americas, and China. The new legal entity, TDK Asia-Pacific Pvt. Ltd., together with TDK Singapore Pte. Ltd., will govern more than 20 TDK entities across India, Southeast Asia and Oceania—representing nearly 17 percent of TDK’s 105,000 team members. Effective 1 April 2026, the APAC RHQ will operate from a dual-city administrative structure: Bengaluru, India, and Singapore, together the epicenter of one of the world’s most consequential economic corridors and drive ‘TDK Transformation’.

Asia-Pacific is the growth market of this century. Home to nearly 40 percent of the world’s population, the region is projected by the IMF to grow at 4.5 percent in 2025, contributing roughly 60 percent of all incremental world output—even as global growth holds at a modest 3.2 percent. Within it, India stands decisively apart: at 6.6 percent GDP growth for FY2025/26 (IMF), the fastest-growing major economy on earth for the third consecutive year, and now the world’s fourth largest after surpassing Japan in 2025. For TDK, this is familiar terrain approached with new ambition. The company has operated in India for several decades, through its two principal business entities—Electronics Components Business Company (ECBC) and Energy Solutions Business Company (ESBC)—and their subsidiaries, with production facilities in West Bengal, Maharashtra, and Haryana. Today, TDK in India employs over 5,000 people.

“With the establishment of the Asia-Pacific RHQ, we are not simply expanding our footprint—we are strengthening the foundation for the future”, said Vaidyanathan Ramasarma, General Manager, APAC RHQ – TDK Corporation. “This region holds immense potential in technology, talent, and market development. Our mission is to unlock that potential responsibly, collaboratively, and strategically.”

The dual-city administrative structure will balance growth and governance equally in a region that demands both. Bengaluru anchors the growth agenda—India’s technology capital with one of the world’s deepest talent ecosystems in engineering, and foundational research, positions TDK to build new categories, not merely optimize existing ones. The APAC RHQ will invest in emerging technology domains, leveraging India’s tradition of frugal engineering and favorable unit economics for a growing global marketplace. Singapore anchors governance, compliance, and supply chain—a trusted, neutral fulcrum for a region of extraordinary complexity. Together, the two cities form a strategic dyad: one looking inward at the intricacies of regional operations, the other at the horizon of what is possible.

The APAC RHQ will strengthen market intelligence, government relations, and supply chain resilience across the region while driving internal efficiencies, workforce skilling, and disciplined process governance—the less visible but indispensable work of building a business that lasts. In particular, APAC RHQ will play a critical role in building TDK’s global R&D network. India’s scientific talent, its appetite for foundational research, and its unique ability to apply deep knowledge to real‑world constraints make it an indispensable part of our global R&D vision. The government of India’s urgency and appetite for foreign direct investment, its improving ease of doing business, and its ambitious national technology initiatives create conditions that are, for a company like TDK, genuinely rare.

For the past two years, a quiet but purposeful effort has been underway—building the relationships, the institutional trust, and the operational foundations needed for success. TDK’s nascent APAC team has been forging partnerships across academia, government, and industry in India, establishing the connective tissue of a long-term commitment.

Through this APAC RHQ, TDK will strengthen its contributions to social transformation from India and Asia‑Pacific, while also accelerating our own transformation.

About TDK Corporation

TDK Corporation (TSE: 6762) is a global technology company and innovation leader in the electronics industry, based in Tokyo, Japan. With the tagline “In Everything, Better” TDK aims to realize a better future across all aspects of life, industry, and society. For over 90 years, TDK has shaped the world from within; from the pioneering ferrite cores to cassette tapes that defined an era, to powering the digital age with advanced components, sensors, and batteries, leading the way towards a more sustainable future. United by TDK Venture Spirit, a start-up mentality built on visions, courage and mutual trust, TDK’s passionate team members around the globe pursue better—for ourselves, customers, partners, and the world. Today, the state-of-the-art technologies of TDK are in everything, from industrial applications, energy systems, electric vehicles, to smartphones and gaming, at the core of modern life. TDK’s comprehensive, innovative-driven portfolio includes cutting-edge passive components, sensors and sensor systems, power supplies, lithium-ion and solid-state batteries, magnetic heads, AI and enterprise software solutions, and more—featuring numerous market-leading products. These are marketed under the product brands TDK, EPCOS, InvenSense, Micronas, Tronics, TDK-Lambda, TDK SensEI, and ATL.  Positioning the AI ecosystem as a key strategic area, TDK leverages its global network across the automotive, information and communication technology, and industrial equipment sectors to expand its business in a wide range of fields. In fiscal 2025, TDK posted total sales of USD 14.4 billion and employed about 105,000 people worldwide.

You can download this text and associated images from https://www.tdk.com/en/news_center/press/20260302_03.html

Contacts for regional media

SUZHOU, China, March 2, 2026 /PRNewswire/ — In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its independently developed, off-the-shelf, allogeneic, universal, iPSC-derived, subtype-specific neuron progenitor cell therapy targeting Multiple System Atrophy- Parkinsonian Type (MSA-P). This joins the previous three consecutive FDA-NMPA registrational trial clearances for its universal iPSC-derived cell therapies targeting Parkinson’s Disease (PD), Spinal Cord Injury (SCI), and Amyotrophic Lateral Sclerosis (ALS), respectively. Building on its promising clinical data, the rapid pipeline progress fully attests to XellSmart’s expertise in iPSC-for-CNS space, the potential clinical value and viability for its products, and its unwavering commitment in addressing the unmet clinical needs in the highly underserved neurodegenerative disease field. 

MSA, recognized by the World Health Organization (WHO) as a rare and fatal neurodegenerative disease with huge unmet needs, meets with this commitment. The Parkinsonian type of multiple system atrophy (MSA-P) mainly presents with progressive Parkinsonian syndrome, such as bradykinesia, rigidity, and gait disorders, accompanied by severe autonomic nerve dysfunction, including orthostatic hypotension and urinary incontinence. This disease is triggered by abnormal aggregation of α-synuclein in oligodendrocytes, causing extensive loss of neuronal function and rapid progress. The median survival for patients after diagnosis is merely 6 to10 years. 

Although MSA-P has a wider pathological scope than Parkinson’s disease, the two diseases overlap to a certain extent in their pathogenesis, especially in the manifestation of Parkinsonian motor symptoms. The current standard clinical treatment for MSA-P includes dopaminergic drugs for Parkinson’s-like motor symptoms, such as levodopa/carbidopa, combined with other dopaminergic therapies when necessary. However, the overall response is often not as good as that for Parkinson’s disease and the efficacy is limited. Non-pharmacological treatments for MSA-P includes management of autonomic dysfunction and rehabilitation training, fall prevention and nutritional support to maintain patients’ physical function and quality of life as much as possible. 

Currently, there are no approved therapies anywhere in the world that can effectively slow or reverse the disease progression. Yet, XellSmart’s innovative approach attempts to address this challenging neurodegenerative disease. Through employing a potential mechanism of regenerating dopamine secretion and promoting circuit and brain environment repair, it explores this novel treatment approach for MSA-P, and the potential to deliver a new therapeutic option and hope to patients worldwide.

Standing at the Forefront of iPSC-derived Cell Therapies for CNS Diseases 

This pipeline extension into MSA-P naturally taps into XellSmart’s expertise in CNS diseases, evidenced by its multiple cleared “China or global first” INDs. Overall, nine INDs from XellSmart have been cleared by US FDA and China NMPA for Phase I/II registrational clinical trials. These commenced trials employ clinical-grade, allogeneic, universal, off-the-shelf, iPSC-derived cell therapeutic products — the laser-sharp development focus of the company, all targeting major or critical CNS diseases, i.e., Parkinson’s Diseases, Spinal Cord Injury, ALS and MSA-P. The key trials are:

• China Phase I/II & the US Phase I registrational clinical trials, targeting primary Parkinson’s disease, the world’s second most prevalent neurodegenerative disorder. The trial is led by a prestigious National Center for Neurological Disorders — Beijing Tiantan Hospital.
• China’s first randomized, double-blind, controlled clinical trial of universal cell therapy, targeting early-onset Parkinson’s disease. The trial is led by Huashan Hospital Fudan University, a leading National Center for Neurological Disorders.
• China and the US Phase I/II registrational clinical trials targeting MSA-P, projected to be kicked off in 2026.
• China and the US Phase I registrational clinical trials targeting Spinal Cord Injury, employing XellSmart’s potentially First-in-Class product, led by the Third Affiliated Hospital of Sun Yat-sen University.
• China Phase I/II & the US Phase I registrational clinical trials, targeting Amyotrophic Lateral Sclerosis (ALS). The trial employs the first China-developed iPSC-derived cell therapy that had received Orphan Drug Designation from the US FDA in 2023. The trial is led by Peking University Third Hospital.

Key Clinical Results Emerged from PD Registrational Trials

This pipeline extension into MSA-P also builds on XellSmart’s promising clinical data in PD trials. The trials carried out at the National Centers for Neurological Disorders have enrolled more than a dozen patients with moderate to severe PD. After receiving cell transplantation treatment, these patients showed:

• No unexpected safety signals observed to date.
• A positive trend for efficacy indicators such as ‘ON/OFF state’ and MDS-UPDRS motor scores. The average “ON state” has been extended by several hours, coupled with a significant relief in “OFF state”, in contrast to pre-treatment difficulty in movement and significant limitations after medication failure. The time for daily free movement and maintaining a relatively high quality of life has significantly increased.
• A trend of long-term survival and maturation of the engrafted neurons, as brain PET examination suggests potential survival and function from newly generated dopaminergic cells in the putamen region.

The clinical results demonstrated XellSmart’s clinical implementation capability and the significant clinical potential of using iPSC-derived cell therapies via stereotactic neurosurgery for safe and effective PD treatment.

A Strong Market Vote of Confidence Following Regulatory Votes of Confidence

Since its inception in 2021, XellSmart has embraced rapid clinical development and GMP-grade facility upgrade supported by five consecutive years of market-driven funding, collectively led by renowned venture capital firms including FreeS Fund, Qiming Venture Partners, LAV, Sequoia Capital China (Hongshan), 3SBIO and more.

The proceeds from this financing have been boosting its key pipeline products into pivotal validation clinical stages. Additionally, the funds will ensure future commercial roll-out of XellSmart’s products through strengthening XellSmart’s fully-fledged, large-scale, standardized production capacity, quality management and control systems for its off-the-shelf iPSC-derived cell products. A firm market vote of confidence, underpinned by successive regulatory votes of confidence by the NMPA and FDA.

About XellSmart

XellSmart is a clinical-stage, regenerative medicine company focusing on treating CNS diseases with clinical-grade, allogeneic, universal, off-the-shelf, iPSC-derived cell therapies. Founded by Dr. Xiang Li (Michael Lee) in 2021 in Suzhou and Shanghai, China, the company has built up a strong portfolio of global patents and secured US FDA and China NMPA clearance for nine INDs of allogeneic iPSC-derived cell therapies targeting major or critical CNS diseases: Parkinson’s Diseases, Spinal Cord Injury, ALS and MSA-P, moving wholly-owned cell therapeutic products through clinical developments in China and the US, based on its own 5,000㎡ R&D center, B+A-grade GMP manufacturing facility, and quality control center in Shanghai and Suzhou, China. XellSmart, standing at the forefront of iPSC-derived cell therapies for underserved CNS diseases, is committed to transforming this disease treatment landscape and helping millions of suffering patients with its cutting-edge innovation.   

CONTACT:
BD@xellsmart.com

Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease.

SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ — ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven RNA-modulating small molecules to treat rare and genetic diseases, today announced a pivotal clinical and dual regulatory milestone: the first participant has been dosed in the First-in-Human (FIH) Phase 1 clinical trial of its lead candidate, RTX-117. This clinical progress follows the recent clearance by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) of Investigational New Drug (IND) applications for two rare neurological indications: Charcot-Marie-Tooth disease (CMT) and Vanishing White Matter disease (VWM). The pipeline has also received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), enabling the expansion of its clinical program into the United States.

The Phase 1 study is a randomized, double-blind, placebo-controlled, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of RTX-117 in healthy participants, supporting the transition into subsequent clinical trials for patients with CMT and VWM.

Advancing Treatment for Rare Neurological Disorders

The severity of these diseases targeted in ReviR’s clinical trials underscores the urgency of ReviR’s mission, while the clearance further validates the unmet need for patients in China and worldwide:

• Charcot-Marie-Tooth disease (CMT): A spectrum of progressive and debilitating inherited disorders that cause nerve damage, resulting in muscle atrophy and loss of sensation in the extremities, with some subtypes leading to high mortality rates.
• Vanishing White Matter disease (VWM): A progressive and catastrophic leukodystrophy that primarily affects children, leading to irreversible motor decline and cognitive deterioration, often with fatal outcomes.

“The milestone is a testament to the rigor of our preclinical data and the efficiency of our global team,” said Paul August, PhD, Chief Scientific Officer of ReviR. “We are committed to working closely with clinical investigators and patient organizations in China to bring these innovative therapies forward as safely and rapidly as possible.”

“The initiation of dosing in our first-in-human study, coupled with the dual IND clearance in China, marks a transformative leap for ReviR Therapeutics,” added Peng Yue, PhD, CEO of ReviR. “By leveraging our VoyageR AI platform and our integrated cross-border operations in the U.S. and China, we are accelerating the development of our small molecule pipelines designed to address critical gaps where no approved disease-modifying treatments exist.”

VoyageR AI is Fundamental to Disease Strategy

RTX-117 has previously received IND approval and Orphan Drug Designation from FDA, and it is also currently the only pipeline in China granted IND clearance for both CMT and VWM. It was discovered and developed using ReviR’s proprietary VoyageR AI platform in collaboration with XtalPi’s AI+robotics drug discovery engine. By leveraging deep insights into RNA biology and protein translation homeostasis, RTX-117 acts on the Integrated Stress Response (ISR) pathway to restore normal protein expression at the molecular source. Beyond the lead program, the VoyageR platform serves as a powerful engine for precision medicine, identifying chemical starting points based on their specific impact on RNA splicing. This enables the modulation of protein expression at the genetic source, empowering ReviR to target complex neurological conditions, immune & inflammatory pathways, and beyond – that have long been considered “undruggable.”

About ReviR Therapeutics

ReviR Therapeutics is a global biotechnology company committed to discovering and developing innovative therapies for patients with serious genetic diseases. ReviR was founded in 2021 by leaders in computational biology, RNA biology, genomics, and drug discovery, with the aim to create disease-modifying therapies that are highly specific, efficacious, and safe. ReviR’s lead candidate, RTX-117, is an investigational small molecule therapy for Charcot-Marie-Tooth disease (CMT)/Vanishing White Matter disease (VWM). In addition, ReviR’s pipeline includes other orally administered small molecules designed to modulate RNA function by splicing. For more information about ReviR Therapeutics, visit www.revirtx.com.

About RTX-117

RTX-117 is a potential first-in-class, orally administered small molecule therapy developed by ReviR Therapeutics, with discovery and molecular design powered by XtalPi’s AI and robotics drug discovery platform. The therapy targets the Integrated Stress Response (ISR) pathway by activating eIF2B, a key protein translation initiation factor. By restoring protein synthesis homeostasis and improving neuromuscular function, RTX-117 aims to address the underlying molecular pathology of related genetic disorders. The candidate is currently undergoing a Phase 1 clinical trial, with Investigational New Drug (IND) clearance already secured for both Charcot-Marie-Tooth disease (CMT) and Vanishing White Matter disease (VWM).

Forward-Looking Statements

This press release contains forward-looking statements regarding ReviR Therapeutics’ clinical trials and regulatory pathways. Actual results may differ materially based on clinical outcomes and regulatory decisions.